$2.27
-0.34 (-13.03%)
Open$2.64
Previous Close$2.61
Day High$2.65
Day Low$2.24
52W High$7.92
52W Low$1.22
Volume—
Avg Volume19.61M
Market Cap28.15M
P/E Ratio—
EPS$-1.58
SectorBiotechnology
Analyst Ratings
Strong Buy
6 analysts
Price Target
+1,099.1% upside
Current
$2.27
$2.27
Target
$27.22
$27.22
$16.99
$27.22 avg
$37.92
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 84.2K | 114.3K | 4.38M |
| Net Income | -16,778,258 | -20,494,614 | -1,275,702 |
| Profit Margin | -19,894.6% | -18,899.9% | -29.1% |
| EBITDA | -5,225,542 | -6,737,601 | -1,970,058 |
| Free Cash Flow | — | — | -1,043,157 |
| Rev Growth | -26.3% | -26.3% | +7.3% |
| Debt/Equity | — | — | 0.26 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.87 | -1.20% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $354.05 | +0.63% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.73 | +0.98% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $449.71 | +0.71% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $776.21 | +0.46% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $330.87 | +4.68% | 139.7 | 43.84B |